Accessibility Menu
Alvotech logo

Alvotech(NASDAQ) ALVO

Market Cap$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-58%
5 YearN/A
1 Year-55%
1 Month+15%
$4.10
+14.71%
+0.53Today
After hours$4.06-$0.04 (-0.86%)
Alvotech last closing stock price
MetricPriceDate
Last closeUSD 4.122026-07-31
Alvotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+34.64%USD 3.062026-07-24
1 month+15.08%USD 3.582026-07-01
3 month+19.08%USD 3.462026-05-01
Year to date-19.69%USD 5.132025-12-31
1 year-54.53%USD 9.062025-07-31
3 year-56.95%USD 9.572023-08-01
Since inception-57.74%USD 9.752020-11-09

Alvotech Financials at a Glance

Market Cap

$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$559.42M

Net Income (TTM)

-$80.73M

EPS (TTM)

-$0.26

P/E Ratio

-15.61

Dividend

$0.00

Beta (Volatility)

0.23 (Low)

Price

$4.10

Volume

1,721,179.116

Open

$3.58

Previous Close

$4.12

Daily Range

$3.54 - $4.12

52-Week Range

$2.94 - $9.25

Estimated Earnings Date

Aug 19, 2026

ALVO News

biotech

Why Shares of Alvotech Are Jumping Friday

James HalleyJun 30, 2023
Pharmaceutical factory worker

Why Shares of Alvotech Jumped This Week

James HalleyDec 8, 2022

ALVO: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alvotech

Alvotech is a biotechnology company focused on the global development and manufacturing of biosimilar pharmaceuticals. The company offers a diverse range of products targeting various therapeutic areas, including autoimmune diseases, eye disorders, bone diseases, and cancer.

Products and Services
  • AVT02: A biosimilar to Humira for inflammatory diseases
  • AVT04: A biosimilar to Stelara for treating psoriatic arthritis and Crohn's disease
  • AVT06: A biosimilar to Eylea for age-related macular degeneration
Growth Outlook
  • Strong pipeline with multiple biosimilars in various stages of development
  • Increasing global demand for affordable biologics supports growth potential
  • Strategic partnerships may enhance market access and distribution
Financial Highlights
  • Q1 2026 revenue of $105.9 million, showing resilience in a challenging market
  • Trailing twelve months (TTM) gross profit margin at 61.4%, indicating operational efficiency
  • Current ratio of 1.76 suggests strong liquidity position
Alvotech has established itself as a key player in the biosimilar market, with a focus on addressing unmet medical needs through innovative products. The company's flagship programs, such as AVT02 and AVT04, are designed to provide effective alternatives to existing therapies, potentially improving patient access to essential medications. The growth outlook remains promising, driven by a robust pipeline and increasing demand for cost-effective treatment options. Recent financial performance indicates a solid foundation, with significant revenue generation and a healthy gross profit margin, positioning Alvotech favorably for future expansion.
AI Generated • Jul 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,460

CEO

Vilhelm Róbert Wessman

Website

www.alvotech.com

Headquarters

Luxembourg, LU L-1273, LU

ALVO Financials

Key Financial Metrics (TTM)

Gross Margin

61.35%

Operating Margin

13.80%

Net Income Margin

-14.43%

Return on Equity

35.22%

Return on Capital

6.72%

Return on Assets

-5.68%

Earnings Yield

-6.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

390.43M

Volume

1.72M

Avg. Volume

802.93K

Financials (TTM)

Gross Profit

$343.22M

Operating Income

$77.22M

EBITDA

$51.83M

Operating Cash Flow

-$123.18M

Capital Expenditure

-$87.30M

Free Cash Flow

-$210.47M

Cash & ST Invst.

$63.83M

Total Debt

$1.46B

Alvotech Performance Analysis

Alvotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 83,029,000N/A
20232023-12-31USD 91,434,00010.1%
20242024-12-31USD 489,682,000435.6%
20252025-12-31USD 586,321,00019.7%
Alvotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3030.5%
Q32025-09-30-34.2%
Q42025-12-3146.0%
Q12026-03-31-36.4%
Alvotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.60N/A
20232023-12-31USD -2.43-6.5%
20242024-12-31USD -0.87-64.4%
20252025-12-31USD 0.10N/A
Alvotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-71.4%
Q32025-09-30-117.4%
Q42025-12-31-2371.3%
Q12026-03-31100.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$105.87M

-20.3%

Gross Profit

$59.78M

-11.2%

Gross Margin

56.47%

N/A

Market Cap

$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.10M

N/A

Employees

1,460

N/A

Net Income

$1.03M

-99.1%

EBITDA

$52.08M

-62.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$63.83M

+65.6%

Total Debt

$1.46B

+18.8%

Accounts Receivable

$106.87M

-53.3%

Inventory

$228.02M

+60.5%

Long Term Debt

$1.40B

+18.5%

Short Term Debt

$55.64M

+27.0%

Return on Assets

-5.68%

N/A

Return on Invested Capital

6.65%

N/A

Free Cash Flow

-$106.62M

-885.3%

Operating Cash Flow

-$60.43M

-581.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAHCPhibro Animal Health Corporation
$36.33-0.33%
HROWHarrow Health, Inc.
$38.77-0.44%
UFPTUFP Technologies, Inc.
$254.78-0.10%
BHVNBiohaven Ltd.
$13.50-2.32%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ALVO

What is the current price of Alvotech?

Alvotech is trading at $4.12 per share.

What is the 52-week range for Alvotech?

Over the past 52 weeks, Alvotech has traded between $2.94 and $9.25.

How much debt does Alvotech have?

As of the most recent reporting period, Alvotech reported total debt of $1.46B.

How much cash does Alvotech have on hand?

Alvotech reported $63.83M in cash and cash equivalents in its most recent financial results.

What is Alvotech’s dividend yield?

Alvotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services